Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928097 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL627257 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL278256 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL23988087 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24928198 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24928774 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24927970 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL16197804 | 0.97 | CYP2B6 (0.41) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL23251488 | 0.97 | CYP2B6 (0.41) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL179261 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681877-B1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-10-16 | — | — | EP | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| US-7244735-B2 | Heterocyclic protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244735-B2 | Heterocyclic protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CYP2B6 666/4885GRIN2D 1051/4885GRIN3B 955/4885 |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | CYP2B6, CYP2D6, CYP4B1 | CYP2B6 1/4885GRIN2D 1390/4885GRIN3B 532/4885 |
| US-20050065144-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | CYP2B6 369/4885GRIN2D 2009/4885GRIN3B 1194/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | CYP2B6 844/4885GRIN2D 395/4885GRIN3B 299/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | CYP2B6 2428/4885GRIN2D 569/4885GRIN3B 31/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | CYP2B6 361/4885GRIN2D 3020/4885GRIN3B 2414/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | CYP2B6 3309/4885GRIN2D 4344/4885GRIN3B 3821/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | CYP2B6 3624/4885GRIN2D 779/4885GRIN3B 340/4885 |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | OPRM1, OPRL1, OPRD1 | CYP2B6 283/4885GRIN2D 1082/4885GRIN3B 447/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CYP2B6 197/4885GRIN2D 1294/4885GRIN3B 440/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | CYP2B6 2870/4885GRIN2D 3850/4885GRIN3B 3861/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | CYP2B6 3297/4885GRIN2D 4131/4885GRIN3B 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.